8-K: CorMedix Reports Strong Q4, Full-Year 2025 Results

CorMedix Inc. announced robust financial results for the fourth quarter and full year ended December 31, 2025, driven by DefenCath sales and the Melinta acquisition.

Summary

• Net revenue for Q4 2025 was $128.6 million, a significant increase from $31.2 million in Q4 2024.
• DefenCath sales contributed $91.2 million of net revenue in Q4 2025.
• Full-year 2025 total revenue reached $311.7 million, with pro forma total revenue of $401.3 million, reflecting full-year contribution from the Melinta portfolio.
• Net income for Q4 2025 was $14.0 million, or $0.16 per diluted share.
• Full-year 2025 net income was $163.0 million, or $2.04 per diluted share, a substantial improvement from a net loss of $17.9 million in 2024.
• Adjusted EBITDA for Q4 2025 was $77.2 million, up from $15.3 million in Q4 2024.
• Total operating expenses for Q4 2025 were $48.2 million, an increase of 182% year-over-year, primarily due to the Melinta acquisition and related costs.
• Cash and short-term investments, excluding restricted cash, stood at $148.5 million as of December 31, 2025.
• CorMedix reiterated its 2026 guidance, projecting net revenue between $300 million and $320 million and adjusted EBITDA between $100 million and $125 million.
• The Board of Directors approved a share repurchase program authorizing up to $75 million of the company's common stock.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, highlighting strong financial performance, successful integration of an acquisition, and clear strategic initiatives including a share repurchase program and progress in key clinical trials.

Positives

• Significant increase in Q4 2025 Net Revenue to $128.6 million, largely driven by DefenCath utilization and the Melinta acquisition.
• Strong full-year 2025 Net Income of $163.0 million, representing a substantial turnaround from a net loss in 2024.
• Adjusted EBITDA for Q4 2025 surged to $77.2 million, indicating improved operational profitability.
• Successful integration and contribution of the Melinta portfolio, adding $37.4 million in Q4 revenue.
• Approval of a $75 million share repurchase program, signaling confidence in future value and commitment to shareholder returns.
• Healthy cash and short-term investments balance of $148.5 million provides financial flexibility.
• Progress in Phase 3 clinical programs for REZZAYO prophylaxis and DefenCath in TPN patients, indicating future growth potential.

Negatives

• Q4 2025 diluted EPS of $0.16 was lower than Q4 2024 diluted EPS of $0.20, despite higher net income, due to an increased weighted average common shares outstanding.
• Total operating expenses increased by 182% in Q4 2025 and 101% for the full year, primarily driven by the Melinta acquisition and associated integration costs.
• Q4 2025 net income included a $42.4 million tax expense primarily associated with the utilization of deferred tax assets.

Risks

• Actual results may differ materially from projections or estimates due to a variety of important factors.
• Forward-looking statements are subject to risks and uncertainties, as detailed in CorMedix's SEC filings, including its most recent Annual Report on Form 10-K.

Future Outlook

CorMedix reiterates its 2026 guidance for net revenue between $300 million and $320 million and adjusted EBITDA between $100 million and $125 million. The company expects clinical data from the Phase 3 ReSPECT study of REZZAYO in Q2 2026 and targets completion of the Phase 3 study of DefenCath in TPN patients in the first half of 2027. Management is focused on driving business growth and shareholder value over the year ahead.

Management Comments

• "I am proud of the Company’s progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN."
• "With the announcement of our share repurchase program and multiple near-term milestones on the horizon, most notably the Rezzayo ReSPECT phase III data, CorMedix is focused on driving business growth and shareholder value over the year ahead."

Industry Context

StockSavvy.ai notes that CorMedix's expansion into a broader anti-infective portfolio through the Melinta acquisition positions it more competitively in the biopharmaceutical space, diversifying revenue streams beyond DefenCath. The focus on life-threatening conditions and ongoing clinical trials for expanded indications aligns with a growing demand for specialized anti-infective and preventative therapies.

Comparison to Industry Standards

• CorMedix's full-year 2025 revenue growth, particularly the pro forma $401.3 million, demonstrates strong post-acquisition performance, potentially outpacing smaller, single-product biopharmaceutical companies.
• The significant increase in Adjusted EBITDA to $77.2 million in Q4 2025 suggests improved operational efficiency and synergy realization post-Melinta, a key indicator often sought by investors comparing against peers like Paratek Pharmaceuticals (recently acquired) or smaller infectious disease focused biotechs.
• The $75 million share repurchase program is a strong signal of financial health and management confidence, a practice more commonly seen in mature, profitable companies rather than smaller biotechs, potentially placing CorMedix in a more favorable light compared to development-stage peers.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact from strong financial results, a share repurchase program, and progress in clinical trials, indicating increased shareholder value.
• Customers (outpatient dialysis): Continued utilization and expanded access to DefenCath, ensuring ongoing product availability.
• Patients: Progress in clinical trials for REZZAYO and DefenCath for expanded indications could lead to new treatment options for life-threatening conditions.

Next Steps

• Host a conference call and webcast on March 5, 2026, at 8:30 AM Eastern Time.
• Continue to accelerate the expansion of patient access for DefenCath.
• Drive business growth and shareholder value over the year ahead.
• Anticipate clinical data from the Phase 3 ReSPECT study of REZZAYO in Q2 2026.
• Continue enrollment for the Phase 3 study of taurolidine/heparin catheter lock solution in TPN patients, targeting completion in the first half of 2027.

Key Dates

Recommendation

The company delivered exceptionally strong financial results for Q4 and full-year 2025, demonstrating a significant turnaround to profitability driven by successful product commercialization and a strategic acquisition. The reiteration of robust 2026 guidance, coupled with a substantial share repurchase program and upcoming clinical milestones, indicates strong management confidence and potential for continued shareholder value creation. The diversified product portfolio post-Melinta acquisition also reduces reliance on a single product.

Keywords

CorMedix, CRMD, biopharmaceutical, DefenCath, Melinta, REZZAYO, financial results, Q4 2025, full year 2025, net revenue, adjusted EBITDA, share repurchase, clinical trials, anti-infective